Revelation Biosciences Stock (NASDAQ:REVB)
Previous Close
$0.83
52W Range
$0.70 - $25.26
50D Avg
$1.07
200D Avg
$3.81
Market Cap
$3.06M
Avg Vol (3M)
$1.66M
Beta
0.18
Div Yield
-
REVB Company Profile
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
REVB Performance
Peer Comparison
Ticker | Company |
---|---|
ZVSA | ZyVersa Therapeutics, Inc. |
BWV | Onconetix, Inc. |
KPRX | Kiora Pharmaceuticals, Inc. |
PXMD | PaxMedica, Inc. Common Stock |
PHIO | Phio Pharmaceuticals Corp. |
QNRX | Quoin Pharmaceuticals, Ltd. |
RNAZ | TransCode Therapeutics, Inc. |
HILS | Tharimmune, Inc. |
VRAX | Virax Biolabs Group Limited |
CYTO | Altamira Therapeutics Ltd. |
SONN | Sonnet BioTherapeutics Holdings, Inc. |
ZURA | Zura Bio Limited |